This document discusses complex generics and the challenges involved in developing them. It defines complex generics as medicines that are substitutes for specialized originator products and must demonstrate bioequivalence, but require proving additional "sameness" parameters during development. Developing complex generics faces formulation challenges, intellectual property barriers, clinical trial design issues, and establishing equivalence. They are more difficult to manufacture than simple generics due to the need for precise control over critical parameters like particle size.
This document outlines chemistry, manufacturing, and controls (CMC) requirements for a marketing authorization application of a drug product. It identifies several areas that require further information, clarification, or validation for the drug substance, excipients, manufacturing process, process controls, specifications, and analytical procedures. Key issues noted include a lack of justification for excipient use, incomplete pharmaceutical development reports, missing process validation data, insufficient characterization of impurities, and non-compliance of some specifications and analytical methods with pharmacopeial standards. Additional data is requested to address these deficiencies before the application can be filed.
The document discusses the Common Technical Document (CTD), which is a standardized format for submitting marketing authorization applications for pharmaceuticals to regulatory authorities. The CTD format was developed by the International Conference on Harmonization to streamline the application process across the US, EU, and Japan. It consists of 5 modules covering administrative information, quality, safety, efficacy, and technical documents. The goal of the CTD is to make application reviews more efficient by providing a consistent organization of data across regions.
The document discusses the requirements and contents of an Investigational Medicinal Product Dossier (IMPD) which provides information on the quality, manufacture, and control of investigational medical products (IMPs) used in clinical trials in the European Union. An IMPD includes summaries of nonclinical and clinical data and is required for authorization to perform clinical trials in EU member states. It must provide an overall risk-benefit assessment of the proposed trial based on nonclinical and clinical analyses. A simplified IMPD may be acceptable in some cases such as if the IMP is already authorized. The IMPD covers quality data, nonclinical pharmacology and toxicology data, previous clinical experience, and an overall risk assessment.
Investigational new drug ,orange book,understanding on 505(b) (2) applicationsswrk
This document discusses investigational new drug applications, the Orange Book, and 505(b)(2) applications. It provides an overview of the IND process including when an IND is needed, the content of an IND application, annual reporting requirements, and classifications of INDs. It also describes the Orange Book's listing of approved drugs and their therapeutic equivalence ratings. Finally, it gives a brief explanation of 505(b)(2) applications, including what products are allowed and examples of 505(b)(2) NDAs.
regulations for combination products .KeerthanaN20
Combination product includes:
(1) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
(2) Two or more separate products packaged together in a single package or as a unit .
(3) A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose;
This slide outlines the evaluation methods of various Controlled Drug Delivery Systems (CDDS) used in the pharmaceutical industry. The controlled Drug Delivery Systems release the drug to the plasma at a controlled, pre-determined level to ensure prolonged and adequate drug supply for a longer time. The slide analyses the various evaluation methods, its pharmacokinetic properties and applications of the evaluation methods in various scenario.
This document outlines chemistry, manufacturing, and controls (CMC) requirements for a marketing authorization application of a drug product. It identifies several areas that require further information, clarification, or validation for the drug substance, excipients, manufacturing process, process controls, specifications, and analytical procedures. Key issues noted include a lack of justification for excipient use, incomplete pharmaceutical development reports, missing process validation data, insufficient characterization of impurities, and non-compliance of some specifications and analytical methods with pharmacopeial standards. Additional data is requested to address these deficiencies before the application can be filed.
The document discusses the Common Technical Document (CTD), which is a standardized format for submitting marketing authorization applications for pharmaceuticals to regulatory authorities. The CTD format was developed by the International Conference on Harmonization to streamline the application process across the US, EU, and Japan. It consists of 5 modules covering administrative information, quality, safety, efficacy, and technical documents. The goal of the CTD is to make application reviews more efficient by providing a consistent organization of data across regions.
The document discusses the requirements and contents of an Investigational Medicinal Product Dossier (IMPD) which provides information on the quality, manufacture, and control of investigational medical products (IMPs) used in clinical trials in the European Union. An IMPD includes summaries of nonclinical and clinical data and is required for authorization to perform clinical trials in EU member states. It must provide an overall risk-benefit assessment of the proposed trial based on nonclinical and clinical analyses. A simplified IMPD may be acceptable in some cases such as if the IMP is already authorized. The IMPD covers quality data, nonclinical pharmacology and toxicology data, previous clinical experience, and an overall risk assessment.
Investigational new drug ,orange book,understanding on 505(b) (2) applicationsswrk
This document discusses investigational new drug applications, the Orange Book, and 505(b)(2) applications. It provides an overview of the IND process including when an IND is needed, the content of an IND application, annual reporting requirements, and classifications of INDs. It also describes the Orange Book's listing of approved drugs and their therapeutic equivalence ratings. Finally, it gives a brief explanation of 505(b)(2) applications, including what products are allowed and examples of 505(b)(2) NDAs.
regulations for combination products .KeerthanaN20
Combination product includes:
(1) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
(2) Two or more separate products packaged together in a single package or as a unit .
(3) A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose;
This slide outlines the evaluation methods of various Controlled Drug Delivery Systems (CDDS) used in the pharmaceutical industry. The controlled Drug Delivery Systems release the drug to the plasma at a controlled, pre-determined level to ensure prolonged and adequate drug supply for a longer time. The slide analyses the various evaluation methods, its pharmacokinetic properties and applications of the evaluation methods in various scenario.
The Hatch-Waxman Act established regulations for generic drugs in the US to facilitate generic competition. It created an Abbreviated New Drug Application process for generics to gain approval more quickly by showing bioequivalence to branded drugs. The first generic to challenge a patent via Paragraph IV certification gains 180 days of marketing exclusivity. The Act also allows patent term extensions for branded drugs to compensate for regulatory approval times. While increasing generic competition, it provides benefits to branded manufacturers such as data and market exclusivities as well as patent dispute resolutions.
This document discusses post-approval regulatory affairs for drugs and medical devices. It explains that the FDA may require post-approval studies to ensure continued safety and effectiveness of approved products. Sponsors must comply with post-approval requirements or approval can be withdrawn. Post-approval changes are categorized as major, moderate, or minor depending on their potential effect. Major changes generally require prior approval from the FDA, while moderate changes require notification 30 days before distribution. Minor changes are reported annually. The document provides recommendations for common post-approval changes including components, manufacturing sites, processes, specifications, packaging, and labeling.
The document discusses the Common Technical Document (CTD) and electronic CTD (eCTD) formats used for submitting registration documents to international regulatory agencies. The CTD format organizes documents into 5 modules: Module 1 contains administrative information specific to each region; Module 2 contains summaries of quality, non-clinical, and clinical information; Module 3 contains quality/manufacturing data; Module 4 contains non-clinical study reports; and Module 5 contains clinical study reports. The eCTD format is the electronic version of CTD, with documents in PDF format linked together via an XML backbone for easier navigation and review compared to the paper CTD format.
WHO Guideline & Stability Protocols for Liquid Dosage FormsAnindya Jana
This document summarizes WHO guidelines for stability testing of liquid dosage forms. It outlines the key aspects that should be covered in stability protocols, including specifications tested, storage conditions and minimum time periods for long term, intermediate and accelerated studies. Specific recommendations are provided for drug substances, oral solutions, suspensions, small volume parenterals and other dosage forms. The purpose of stability testing is to provide evidence of a product's quality over time under various environmental factors and establish a re-test period or shelf life. Ongoing stability studies are also required to monitor products throughout their shelf life.
The document provides guidance on post-approval changes to immediate release solid oral dosage forms. It defines three levels (I, II, III) of changes based on their potential impact. Level I changes are minor, Level II are moderate, and Level III are major. It provides recommendations for chemistry, manufacturing, dissolution and bioequivalence testing for components/composition, site, batch size and manufacturing changes. Changes are supported by prior approval supplements, changes being effected supplements or annual reports with stability data as appropriate to the level of change.
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
This document discusses approaches for demonstrating bioequivalence of complex generic drug products. It begins with an overview of the pre-ANDA program for complex generics, including product development meetings, pre-submission meetings, and mid-review cycle meetings. It then discusses specific challenges and considerations for complex active ingredients like peptides, as well as example complex drug products like sevelamer carbonate tablets and ophthalmic ointments and suspensions. The document emphasizes that demonstration of bioequivalence for complex generics often requires alternative approaches like in vitro studies and physiochemical characterization due to challenges with clinical endpoint studies.
This document defines combination products and medical devices and discusses their classification and regulatory requirements. Combination products involve two or more regulated products combined in a single package. Medical devices are instruments or articles used for diagnosis, prevention, monitoring or treatment of disease. The document outlines the classification of medical devices into Classes I-III based on risk and the regulatory pathways of 510(k), reclassification, product development protocol, de novo review, and premarket approval.
Post-marketing surveillance (PMS) involves monitoring pharmaceutical drugs and medical devices after they have been released to the public to identify adverse drug reactions (ADRs) that were not detected in pre-market clinical trials due to limitations such as narrow study populations and durations. PMS benefits include identifying low frequency ADRs, effects in high risk groups, long term effects, and drug interactions. Information is collected through expert user groups, customer surveys, complaints, literature reviews, and media reports. PMS studies use controlled clinical trials, spontaneous reporting, cohort studies, and case control studies to identify drug effects.
Combinational products & medical devicesSHUBHAMGWAGH
This document provides an overview of regulations for combination products and medical devices in India. It defines combination products as those composed of two or more medical products like drugs, devices, and/or biologics. The regulatory authorities in India that oversee drugs and medical devices are described, including the Drugs Controller General of India and Central Drugs Standard Control Organization. The document outlines some key proposed regulations like the Indian Medical Device Regulatory Act, which would classify medical devices into four risk-based categories and establish design, manufacturing, and post-market surveillance requirements. It also discusses the role of pharmacists in understanding medical device safety and being involved in their regulation.
This document discusses various oral controlled release drug delivery systems. It describes dissolution controlled systems like encapsulation and matrix dissolution control where drug release is controlled by the rate of dissolution of a coating. Diffusion controlled systems like reservoir and matrix devices are also discussed where the rate of drug release depends on diffusion through a coating membrane. Combined dissolution and diffusion systems and ion exchange resins are also summarized. The document provides details on different types of controlled release tablets and their drug release mechanisms.
The document discusses regulatory guidelines for pharmaceutical excipients and their development. It notes that the International Pharmaceutical Excipient Council promotes quality standards for excipients to ensure drug product efficacy, safety and stability. The document outlines challenges in developing new excipients and coprocessing APIs with excipients. It also discusses establishing excipient functionality through specifications and harmonizing pharmacopoeial standards for excipients.
This presentation includes information related to the different technologies used for preparation of micro-capsules and also their evaluation parameters.
The document discusses the Common Technical Document (CTD) format and electronic CTD (eCTD) format for new drug applications. The CTD format was agreed upon in 2000 and standardized the organization of application modules for quality, nonclinical, and clinical information. The eCTD is the electronic equivalent that regulatory agencies now require for application submissions. Key benefits of the eCTD include increased efficiency, reduced costs, and improved review processes through electronic submission and evaluation of drug applications.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...PRAJAKTASAWANT33
The document presents information on regulatory requirements for investigational medicinal products (IMPs) and investigational medicinal product dossiers (IMPDs) in the European Union. It defines an IMP as a pharmaceutical product used in a clinical trial, including products with marketing authorization being tested differently than approved. A full or simplified IMPD must be submitted and approved as part of a clinical trial authorization application. The IMPD contains quality, non-clinical and clinical data about the IMP to assess risks and benefits before trials.
This document provides information on drug master files (DMFs), including:
- There are 5 types of DMFs which contain information on drug substances, packaging materials, excipients, and other reference materials.
- A Type II DMF contains information about drug substances and products, and must be submitted in ICH CTD format.
- Modules 1-3 of the CTD are included in a DMF, with Module 1 containing administrative information, Module 2 providing a quality overall summary, and Module 3 containing detailed information on manufacturing, characterization, and controls.
- DMF holders must notify authorized parties of any amendments and provide annual reports on the anniversary of the original submission.
This document provides information on regulatory requirements for obtaining marketing authorization in Rest of World (ROW) countries for pharmaceutical products. It discusses that while some regions like ASEAN and GCC have partially harmonized regulations, ROW countries overall still have diverse regulatory environments. The International Council for Harmonisation is working to standardize quality, safety and efficacy reporting formats in applications. Requirements for various individual countries are also reviewed, along with commonly used application forms in India under the Drugs and Cosmetics Act.
Rate limiting steps in drug absorption [autosaved]Nagaraju Ravouru
Rate limiting steps in drug absorption 1.Disintegration time
2.Dissolution and solubility
3.Physical and chemical nature of active drug substance
4.Nature of excipients
5.Method of granulation
6.Dissolution test conditions
7.Gastric emptying
Novel drug delivery systems aim to optimize drug pharmacokinetics, reduce toxicity, and increase efficacy and bioavailability. They include polymers, micro/nanoparticles, liposomes, micelles, and hydrogels that can encapsulate, protect, target, and gradually release drugs. These systems help minimize harmful side effects, maximize drug accumulation at target sites, and overcome biological barriers to treatment of severe diseases.
The document discusses generic drugs and biosimilars. It provides biographical information about the speaker and outlines key questions about generics that will be addressed. Generic drugs are defined as comparable but not identical to brand name drugs in dosage, strength, quality and performance. Biosimilars are similar to biologic drugs but require more extensive testing than generics due to their complex nature. The market for generic drugs is large and growing, particularly in emerging markets, as major drugs lose patent protection.
The Hatch-Waxman Act established regulations for generic drugs in the US to facilitate generic competition. It created an Abbreviated New Drug Application process for generics to gain approval more quickly by showing bioequivalence to branded drugs. The first generic to challenge a patent via Paragraph IV certification gains 180 days of marketing exclusivity. The Act also allows patent term extensions for branded drugs to compensate for regulatory approval times. While increasing generic competition, it provides benefits to branded manufacturers such as data and market exclusivities as well as patent dispute resolutions.
This document discusses post-approval regulatory affairs for drugs and medical devices. It explains that the FDA may require post-approval studies to ensure continued safety and effectiveness of approved products. Sponsors must comply with post-approval requirements or approval can be withdrawn. Post-approval changes are categorized as major, moderate, or minor depending on their potential effect. Major changes generally require prior approval from the FDA, while moderate changes require notification 30 days before distribution. Minor changes are reported annually. The document provides recommendations for common post-approval changes including components, manufacturing sites, processes, specifications, packaging, and labeling.
The document discusses the Common Technical Document (CTD) and electronic CTD (eCTD) formats used for submitting registration documents to international regulatory agencies. The CTD format organizes documents into 5 modules: Module 1 contains administrative information specific to each region; Module 2 contains summaries of quality, non-clinical, and clinical information; Module 3 contains quality/manufacturing data; Module 4 contains non-clinical study reports; and Module 5 contains clinical study reports. The eCTD format is the electronic version of CTD, with documents in PDF format linked together via an XML backbone for easier navigation and review compared to the paper CTD format.
WHO Guideline & Stability Protocols for Liquid Dosage FormsAnindya Jana
This document summarizes WHO guidelines for stability testing of liquid dosage forms. It outlines the key aspects that should be covered in stability protocols, including specifications tested, storage conditions and minimum time periods for long term, intermediate and accelerated studies. Specific recommendations are provided for drug substances, oral solutions, suspensions, small volume parenterals and other dosage forms. The purpose of stability testing is to provide evidence of a product's quality over time under various environmental factors and establish a re-test period or shelf life. Ongoing stability studies are also required to monitor products throughout their shelf life.
The document provides guidance on post-approval changes to immediate release solid oral dosage forms. It defines three levels (I, II, III) of changes based on their potential impact. Level I changes are minor, Level II are moderate, and Level III are major. It provides recommendations for chemistry, manufacturing, dissolution and bioequivalence testing for components/composition, site, batch size and manufacturing changes. Changes are supported by prior approval supplements, changes being effected supplements or annual reports with stability data as appropriate to the level of change.
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
This document discusses approaches for demonstrating bioequivalence of complex generic drug products. It begins with an overview of the pre-ANDA program for complex generics, including product development meetings, pre-submission meetings, and mid-review cycle meetings. It then discusses specific challenges and considerations for complex active ingredients like peptides, as well as example complex drug products like sevelamer carbonate tablets and ophthalmic ointments and suspensions. The document emphasizes that demonstration of bioequivalence for complex generics often requires alternative approaches like in vitro studies and physiochemical characterization due to challenges with clinical endpoint studies.
This document defines combination products and medical devices and discusses their classification and regulatory requirements. Combination products involve two or more regulated products combined in a single package. Medical devices are instruments or articles used for diagnosis, prevention, monitoring or treatment of disease. The document outlines the classification of medical devices into Classes I-III based on risk and the regulatory pathways of 510(k), reclassification, product development protocol, de novo review, and premarket approval.
Post-marketing surveillance (PMS) involves monitoring pharmaceutical drugs and medical devices after they have been released to the public to identify adverse drug reactions (ADRs) that were not detected in pre-market clinical trials due to limitations such as narrow study populations and durations. PMS benefits include identifying low frequency ADRs, effects in high risk groups, long term effects, and drug interactions. Information is collected through expert user groups, customer surveys, complaints, literature reviews, and media reports. PMS studies use controlled clinical trials, spontaneous reporting, cohort studies, and case control studies to identify drug effects.
Combinational products & medical devicesSHUBHAMGWAGH
This document provides an overview of regulations for combination products and medical devices in India. It defines combination products as those composed of two or more medical products like drugs, devices, and/or biologics. The regulatory authorities in India that oversee drugs and medical devices are described, including the Drugs Controller General of India and Central Drugs Standard Control Organization. The document outlines some key proposed regulations like the Indian Medical Device Regulatory Act, which would classify medical devices into four risk-based categories and establish design, manufacturing, and post-market surveillance requirements. It also discusses the role of pharmacists in understanding medical device safety and being involved in their regulation.
This document discusses various oral controlled release drug delivery systems. It describes dissolution controlled systems like encapsulation and matrix dissolution control where drug release is controlled by the rate of dissolution of a coating. Diffusion controlled systems like reservoir and matrix devices are also discussed where the rate of drug release depends on diffusion through a coating membrane. Combined dissolution and diffusion systems and ion exchange resins are also summarized. The document provides details on different types of controlled release tablets and their drug release mechanisms.
The document discusses regulatory guidelines for pharmaceutical excipients and their development. It notes that the International Pharmaceutical Excipient Council promotes quality standards for excipients to ensure drug product efficacy, safety and stability. The document outlines challenges in developing new excipients and coprocessing APIs with excipients. It also discusses establishing excipient functionality through specifications and harmonizing pharmacopoeial standards for excipients.
This presentation includes information related to the different technologies used for preparation of micro-capsules and also their evaluation parameters.
The document discusses the Common Technical Document (CTD) format and electronic CTD (eCTD) format for new drug applications. The CTD format was agreed upon in 2000 and standardized the organization of application modules for quality, nonclinical, and clinical information. The eCTD is the electronic equivalent that regulatory agencies now require for application submissions. Key benefits of the eCTD include increased efficiency, reduced costs, and improved review processes through electronic submission and evaluation of drug applications.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...PRAJAKTASAWANT33
The document presents information on regulatory requirements for investigational medicinal products (IMPs) and investigational medicinal product dossiers (IMPDs) in the European Union. It defines an IMP as a pharmaceutical product used in a clinical trial, including products with marketing authorization being tested differently than approved. A full or simplified IMPD must be submitted and approved as part of a clinical trial authorization application. The IMPD contains quality, non-clinical and clinical data about the IMP to assess risks and benefits before trials.
This document provides information on drug master files (DMFs), including:
- There are 5 types of DMFs which contain information on drug substances, packaging materials, excipients, and other reference materials.
- A Type II DMF contains information about drug substances and products, and must be submitted in ICH CTD format.
- Modules 1-3 of the CTD are included in a DMF, with Module 1 containing administrative information, Module 2 providing a quality overall summary, and Module 3 containing detailed information on manufacturing, characterization, and controls.
- DMF holders must notify authorized parties of any amendments and provide annual reports on the anniversary of the original submission.
This document provides information on regulatory requirements for obtaining marketing authorization in Rest of World (ROW) countries for pharmaceutical products. It discusses that while some regions like ASEAN and GCC have partially harmonized regulations, ROW countries overall still have diverse regulatory environments. The International Council for Harmonisation is working to standardize quality, safety and efficacy reporting formats in applications. Requirements for various individual countries are also reviewed, along with commonly used application forms in India under the Drugs and Cosmetics Act.
Rate limiting steps in drug absorption [autosaved]Nagaraju Ravouru
Rate limiting steps in drug absorption 1.Disintegration time
2.Dissolution and solubility
3.Physical and chemical nature of active drug substance
4.Nature of excipients
5.Method of granulation
6.Dissolution test conditions
7.Gastric emptying
Novel drug delivery systems aim to optimize drug pharmacokinetics, reduce toxicity, and increase efficacy and bioavailability. They include polymers, micro/nanoparticles, liposomes, micelles, and hydrogels that can encapsulate, protect, target, and gradually release drugs. These systems help minimize harmful side effects, maximize drug accumulation at target sites, and overcome biological barriers to treatment of severe diseases.
The document discusses generic drugs and biosimilars. It provides biographical information about the speaker and outlines key questions about generics that will be addressed. Generic drugs are defined as comparable but not identical to brand name drugs in dosage, strength, quality and performance. Biosimilars are similar to biologic drugs but require more extensive testing than generics due to their complex nature. The market for generic drugs is large and growing, particularly in emerging markets, as major drugs lose patent protection.
One mans supergeneric is anothers life cycle managementMalcolm Ross
This document discusses the potential for generic pharmaceutical companies to develop "supergeneric" or value-added generic drug products. It provides examples of how simple reformulations or new delivery methods for off-patent drugs could create differentiated products with improved efficacy or compliance compared to existing generics. Developing combination products or modified release formulations are presented as opportunities requiring relatively little investment that leverage existing technical skills at generic companies.
Biologicals and biosimilars are complex drugs produced by living cells. Biosimilars are similar but not identical copies of biological reference drugs. Regulatory requirements for biosimilars are more extensive than generics but less so than original biological drugs. Biosimilars require comparative quality analysis, limited clinical trials and toxicity studies against the reference drug. Due to inherent structural differences, biosimilars cannot be considered interchangeable with the reference drug.
This document provides an overview of bioequivalence studies and discusses several research papers on topics related to bioequivalence. It begins with definitions of key terms like bioequivalence, branded drugs, generic drugs, and describes the process and criteria for performing bioequivalence studies. Several sections summarize recent research on issues like the role of metabolites in bioequivalence assessment, sex-dependent differences, and bioequivalence of drugs prescribed mainly for women. The document also discusses the importance of clinical research and how various studies contribute to developing the pharmaceutical sector by furthering understanding of bioequivalence.
This document discusses prodrug design. It defines prodrugs as pharmacologically inert derivatives that can be converted in vivo to the active drug molecule. The goals of prodrug design are to overcome undesirable drug properties related to absorption, distribution, metabolism and toxicity. Examples are given of prodrugs that increase oral absorption or provide targeted delivery to tumors. Prodrugs are evaluated based on their physicochemical properties and pharmacokinetic profile to ensure they are converted to the active drug molecule.
This document provides guidelines on bioequivalence requirements for drug products in GCC countries. It defines key terms related to bioequivalence such as pharmaceutical equivalents, generics, innovator products, and more. It explains that multi-source drug products intended to be interchangeable must demonstrate therapeutic equivalence, which can be shown through bioequivalence studies comparing the test product to a reference product. The guidelines provide details on study design for bioequivalence studies, including recommendations for non-replicate and replicate study designs depending on the drug product. It also lists acceptable methodologies for demonstrating equivalence between products.
The release of the drug substance from the drug product leading to the bioavailability of the drug substance. The assessment of drug product performance is imp. Since bioavailability is related both to the pharmacodynamic responses and the adverse events. The performance tests relate the quality of a drug product to clinical safety and efficacy.
Bioavailability studies are drug product performance studies used to define
the effect of changes in the physicochemical properties of the drug substance, the formulation of the drug, and the manufacturing process of the drug product.
This document summarizes guidelines for biosimilars in India. It begins by defining biosimilars as biologic compounds that are similar but not identical to reference biopharmaceuticals. It then discusses several biosimilar drugs used in cancer treatment such as G-CSF, interferons, and epoetins. While biosimilars have similar mechanisms of action, differences in manufacturing can result in differences in properties. The document concludes by outlining Indian regulatory guidelines for biosimilar approval and the importance of post-marketing safety monitoring to evaluate potential differences from reference drugs.
This document discusses biosimilars, which are biologic medications that are similar but not identical to an original biologic reference medication. It provides background on biosimilars and regulatory guidelines around them. Specifically, it notes that biosimilars take 6-9 years to develop compared to 3 years for generics, and that they require clinical trials to demonstrate safety and efficacy compared to the reference medication. The document also discusses biosimilar guidelines in India and examples of biosimilars used in cancer treatment, noting some differences between biosimilar versions of medications like G-CSF and interferons.
The document summarizes novel drug delivery systems (NDDS). It defines NDDS as a new approach combining development, formulations, technologies, and methodologies to safely deliver pharmaceutical compounds as needed. NDDS aim to increase bioavailability, provide controlled delivery, transport drugs intact to target sites, and be stable under physiological conditions. Various approaches under development include micelles, liposomes, dendrimers, liquid crystals, nanoparticles, and hydrogels. These systems aim to minimize drug degradation and loss, prevent side effects, and increase drug levels at target sites. Microencapsulation is also discussed as a process to incorporate materials on a microscale and provide benefits like protecting actives, separating incompatible components, and enabling targeted release.
1) The document provides guidance on in vitro and in vivo evaluation of drug products, including characterization of the drug substance and product through physicochemical properties and dissolution testing.
2) It outlines the types of pharmacokinetic and pharmacodynamic studies that should be conducted to understand how the drug substance and product properties relate to clinical performance.
3) The document emphasizes that in vivo studies are generally needed to demonstrate bioequivalence, but in some cases in vitro studies may suffice, such as for BCS Class I drugs with rapid dissolution.
Bioavailability and bioequivalence are important concepts for regulating generic drugs. Bioavailability refers to the rate and extent that the active drug ingredient is absorbed and available in the body. Bioequivalence means two drug products containing the same active ingredient have the same rate and extent of absorption. For approval, generic drugs must demonstrate bioequivalence to the brand name drug through pharmacokinetic studies comparing metrics like AUC and Cmax between a test and reference drug. The FDA prefers showing bioequivalence through these types of studies using a crossover design in healthy subjects under fasted conditions.
2014.09.30. Bioavailability Enhancement Webinar Series: Optimizing Technology Choice to Enhance Bioavailability
Capsugel (Bend Research)
Abstract:
An increasing number of active compounds in pipelines today have properties that require functional formulation to enable exposure and efficacy. Despite many new technology choices, it is often difficult to match the right drug-delivery technology to a given molecule and problem statement. This problem is exacerbated by the need to save time and valuable drug in early development. This webinar describes an efficient strategy for mating enabling drug-delivery technologies with problem statements based on challenging compound properties and product concepts, building on an understanding of gut physiology, key molecule physicochemical properties, and the target product profile.
Company Summary:
Capsugel Dosage Form Solutions designs, develops and manufactures innovative dosage forms addressing bioavailability and other pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation.
Speakers Bio:
Dr. David Vodak
Vice President Bend Research Moderator
Dr. Vodak's areas of expertise are research and development of novel pharmaceutical drug-delivery systems. Dr. Vodak holds a PhD in materials chemistry from the University of Michigan and a B.A. in chemistry from Willamette University.
Dr. David Lyon
Senior Vice President Bend Research
Dr. Lyon is the Senior Vice President at Bend Research. He leads development activities for new technologies, oversees the development of predictive biomodels, and provides technical leadership to the research groups for new and applied technologies.
This document discusses biodegradable polymers for drug delivery applications. It provides background on limitations of non-degradable systems and advantages of biodegradable polymers, which degrade into non-toxic components and avoid need for device removal. Common biodegradable polymers used are poly(lactic acid), poly(glycolic acid) and their copolymer poly(lactide-co-glycolide), which degrade via hydrolysis of bonds between monomers. These polymers were first developed as degradable sutures and have since been widely used to provide controlled release in applications like contraception and cancer treatment.
This document provides an overview of biosimilars, which are biologic drugs that are similar but not identical to an original biologic drug (the innovator product). It discusses how biosimilars present several challenges due to the complex nature of biologics, which are produced through biotechnology rather than chemical synthesis. Specifically, it notes challenges around verifying similarity between a biosimilar and innovator, determining interchangeability, developing appropriate naming, establishing regulatory frameworks, and ensuring public safety. The document also compares key differences between biologics and traditional small molecule drugs.
Novel Drug Delivery System An OverviewYogeshIJTSRD
In present scenario evolution of an existing drug molecule from a old form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety and efficacy. In the form of a control drug delivery system an existing drug molecule can get a new life. An appropriately designed Novel Drug Delivery System can be a major advance for solving the problems related towards the release of the drug at specific site with specific rate. The porpuse for delivering drugs to patients efficiently and with fewer side effects has prompted pharmaceutical companies to engage in the development of new drug delivery system. This article covers the basic information regarding Novel Drug Delivery Systems and also advantages, factor etc. Chiranjit Barman | Dr. Gaurav Kumar Sharma | Dr. Kausal Kishore Chandrul "Novel Drug Delivery System: An Overview" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021, URL: https://www.ijtsrd.com/papers/ijtsrd45068.pdf Paper URL: https://www.ijtsrd.com/pharmacy/novel-drug-delivery-sys/45068/novel-drug-delivery-system-an-overview/chiranjit-barman
This document provides information about the Phar3191 module on biopharmaceutics and pharmacokinetics. It discusses key concepts in biopharmaceutics including how the physicochemical properties of drugs and dosage forms influence drug absorption and delivery. It describes the mechanisms of drug transport including passive diffusion, carrier-mediated transport, and the barriers drugs must cross like epithelial and plasma membranes. Factors that affect drug absorption like dosage form properties and membrane characteristics are also summarized.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Depression is a state of low mood and lack of interest that affects thoughts, behavior, feelings, and well-being. It has various causes such as genetics, neurotransmitter dysfunction, psychosocial stress, medical illnesses, and endocrine disorders. There are two main types of depression: unipolar, which accounts for 80% of cases, and bipolar disorder. Treatment involves antidepressant drugs which affect serotonin, norepinephrine, and dopamine levels, as well as electroconvulsive therapy for severe cases. The pathophysiology involves both neurotrophic and monoamine hypotheses relating to brain-derived neurotrophic factor levels and deficiencies in cortical monoamines.
Plant hormones, also known as phytohormones, regulate growth and development in plants. There are five major classes of plant hormones: auxins, gibberellins, cytokinins, ethylene, and abscisic acid. Auxins promote cell elongation and differentiation, as well as apical dominance. Gibberellins promote stem elongation. Cytokinins stimulate cell division and differentiation. Ethylene regulates fruit ripening and inhibits stem elongation. Abscisic acid induces seed dormancy. Plant hormones have potential medical applications, as some can inhibit the growth of cancer cells.
Polyploids are organisms with multiple sets of chromosomes beyond the diploid number. They occur naturally and provide mechanisms for adaptation. Euploids are the most common type of polyploid and contain multiples of the basic chromosome set. Autopolyploids contain multiple copies of the same genome, while allopolyploids contain genomes from different species. Polyploids have applications in plant breeding like inducing mutations, producing seedless fruits, and overcoming hybridization barriers. They provide advantages such as increased vigor and stress tolerance, but also drawbacks like effects on sterility and inheritance.
This document discusses hybridization in crop plants to enhance agricultural efficiency and food production. It notes that current food production is not sufficient to feed the growing population. It identifies achieving higher yields on currently cultivated land through crop variety improvement as a key way to enhance efficiency. Crop variety improvement is done through hybridization, which is the crossing of genetically dissimilar plants to obtain crops with desirable traits like disease resistance and higher yields. Hybridization is grouped into two main types - intraspecific involving crosses within a species, and interspecific involving crosses between different species or genera.
This document provides an overview of total quality management (TQM). It defines TQM as managing the whole organization to achieve excellence by focusing on quality. The key elements of TQM include focusing on customers, employee involvement, and continuous improvement. TQM aims to prevent errors and defects through an integrated organizational effort to improve quality at every level from the design of the product or service to its delivery.
ISO 9000 and 14000 are international standards for quality management and environmental management systems. ISO 9000 defines requirements for quality assurance systems to ensure manufacturing and service industries meet customer needs. It is based on seven quality management principles including customer focus, leadership, engagement of people, and evidence-based decision making. ISO 14000 helps organizations develop environmental management systems and meet environmental challenges. It includes standards for environmental management systems, auditing, labeling, and assessing environmental performance and impacts. Both standards provide guidance for organizations to improve products/services, quality, and environmental sustainability.
Calibration is the process of establishing the relationship between measurements indicated by an instrument and known standard values. It involves identifying instruments and sources of standards, following calibration procedures, documenting results, and accounting for sources of error. Key steps include calibrating against certified reference materials and national standards to minimize uncertainty and ensure traceability. Instruments are calibrated using single-point, multi-point or other procedures depending on the instrument type.
A pH meter measures the concentration of hydrogen ions (H+) in a solution using an ion-sensitive electrode. It has a glass electrode and reference electrode in one tube. When measuring pH, a salt bridge forms allowing sodium ions (Na+), not H+, to cross the glass membrane and allow the pH meter to measure the H+ concentration. To calibrate the pH meter, it is placed in high, neutral, and low pH buffer solutions. Litmus paper can also indicate pH but a pH meter provides a more precise measurement. The pH scale ranges from 0-14 with lower numbers indicating more acidity and higher numbers indicating more basicity.
The document discusses the validation of pharmaceutical processes. It defines validation as establishing evidence that a process will consistently produce a product meeting specifications. There are several types of validation covered, including process validation to ensure consistency in manufacturing, cleaning validation to minimize contamination, equipment validation to ensure equipment is fit for use, and analytical method validation to establish testing methods are accurate and reliable. Validation involves extensive documentation like validation master plans, protocols, and reports and aims to maintain high quality standards in the pharmaceutical industry.
This document outlines the key elements of Good Manufacturing Practices (GMP) and cGMP (current GMP). It discusses the definition of GMP, the timeline of GMP regulations from 1902 to 1980, requirements for personnel, premises, equipment, standard operating procedures, batch records, validation processes, and labeling. In summary, it provides an overview of GMP guidelines for pharmaceutical manufacturing facilities covering areas like quality management, facility operations, equipment and materials.
This document outlines various quality control tests performed on pharmaceutical packaging and containers. It discusses QC tests for containers made of glass, plastic, and metal to test for chemical resistance, leakage, pressure resistance, and other properties. It also summarizes QC tests for closures like sterility testing, fragmentation testing, and pH testing of aqueous extracts. Finally, common QC tests for secondary packaging materials like paper and board are mentioned, including moisture content, strength, and barrier property testing. The document provides detailed methods and acceptance criteria for many important packaging quality control tests.
This document discusses the importance and history of informed consent in clinical research. It provides definitions of informed consent from international guidelines and outlines the key principles of voluntary participation, comprehension, and disclosure of information. The summary also highlights some notable events that shaped standards of informed consent, including the Nuremberg Code, Declaration of Helsinki, Belmont Report, and controversies like the Tuskegee Syphilis Study. Required components of informed consent forms are listed from ICMR guidelines in India.
The document discusses the mechanism of drug action, including the molecular targets that drugs bind to produce their pharmacological effects. It explains that the mechanism usually involves specific interactions with targets like enzymes or receptors. It then covers various aspects of mechanisms like the molecular, cellular, tissue and system-level effects of drugs. Various molecular targets that drugs can act on are described, including receptors, enzymes, ion channels, and genetic material. The different types of receptors like ligand-gated ion channels, G-protein coupled receptors, and nuclear receptors are also summarized.
This document discusses various anthelmintic drugs used to treat parasitic worm infections. It begins by defining antihelminthics and describing their mechanisms of action. Common helminth infections are then outlined. The main section discusses individual drugs including their mechanisms, pharmacokinetics, uses, and adverse effects. Drugs covered in detail include mebendazole, albendazole, pyrantel pamoate, piperazine, levamisole, diethylcarbamazine, ivermectin, niclosamide, and praziquantel. The document concludes by noting changes to India's National List of Essential Medicines and emphasizing several important anthelmintics to learn.
Immunostimulants are chemical, drug, stressor or actions that enhance the innate or non-specific immune response in animals by activating immune cells. They include chemical agents, bacterial preparations, polysaccharides, animal or plant extracts, and cytokines. Common immunostimulants used in aquaculture include glucan, levamisole, chitin, and chitosan. Glucan is derived from yeast cell walls and plants and has excellent immuno-stimulatory properties. Levamisole is a synthetic anthelmintic that can also enhance the non-specific immune response in fish. Chitin and chitosan are derived from shrimp and crab shells and have been shown to increase disease resistance
Parkinson's disease is a neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra. The main symptoms are motor symptoms like tremors and rigidity, as well as non-motor symptoms like depression and sleep disorders. Diagnosis is based on the presence of cardinal motor features and there are no definitive medical tests. Current treatments aim to replace dopamine or stimulate dopamine receptors through drugs. Emerging treatments include gene therapy, stem cell therapy, deep brain stimulation surgery, and alternative therapies like acupuncture. Researchers are developing new drug formulations and therapies to better treat Parkinson's symptoms like bradykinesia and tremors that remain problematic.
This document summarizes different classes of oral hypoglycemic drugs used to treat diabetes by lowering blood glucose levels. It discusses 6 classes: sulfonylureas which stimulate insulin secretion from the pancreas; meglitinides which also stimulate insulin secretion; thiazolidinediones which improve insulin sensitivity; alpha glucosidase inhibitors which delay carbohydrate absorption; DPP-4 inhibitors which increase incretin hormones; and biguanides like metformin which decrease glucose production in the liver. Recent FDA-approved diabetes drugs introduced since 2010 that are also summarized include GLP-1 receptor agonists, SGLT2 inhibitors, and their combinations.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
2. GENERICS
A generic product is a medicine that can be prescribed as a
substitute for the originator product because the
bioequivalence has been demonstrated.
The official WHO definition of generic product, i.e.,
interchangeable multisource pharmaceutical product, clearly
recalls this aspect.
To be “generic”, a medicinal product must preliminarily
exhibit the same qualitative and quantitative composition of
active substances and the same dosage form as that of the
originator.
However, pharmaceutical equivalence is not enough: the
generic product must be bioequivalent to the reference
product, that is, it must exhibit the same bioavailability3 or the
same therapeutic effect.
3. FDA points out that therapeutic equivalence comes out from
a demonstrated pharmaceutical equivalence plus
bioequivalence . Only after confirmatory bioavailability
studies the generic product can be used as an
interchangeable medicine.
Thus, the definition of “generic” implies dosage form
sameness; however, in practice exceptions are frequent. For
example, the substitution of a product in tablets with a
bioequivalent product in hard capsules does not seem
illogical.
However, an objection might be made by the patient, who,
despite the declaration of his centric role in drug
administration, is pushed to accept a substitution prescribed
for cost reasons.
Generic substitutions often create complaints and
reconsiderations of approved products, partly because it is
not only the originator product that is substituted, but often
generic products are substituted with other generic ones.
4. COMPLEX GENERICS
A complex generic product is a medicine that can be
prescribed as a substitute for the originator specialized
product because the bioequivalence has been
demonstrated; however it is not as simple as generics
to get manufactured.
To be “complex generic”, a medicinal product must
preliminarily exhibit not only same qualitative and
quantitative composition of active substances and the
same dosage form as that of the originator
but also lots of various other parameters are
considered to prove “sameness”, e.g. physical
characterization like particle size distribution, drug
entrapment, particle morphology, physical state of
entrapped drug, drug release, viscosity, globule size,
zeta potential, excipient characterization etc.
5. Along with formulation development challenges,
other barriers like strong intellectual property
barriers, citizen petitions, facility issues,
unavailability of literature, ambiguity in terms of
bioequivalence/ clinical trial protocol to design,
structural characterization, device sameness, stability
of formulation according to regulatory guidelines and
to establish in-vitro in-vivo equivalence are faced
during development of complex generics.
Complex generics are classified based on possibility
of existing complexity at various stages of product
development. In some instances complexity may exist
in nature of active itself i.e. LMWH, peptides,
complex mixtures, natural source products.
6. It may even exist in formulation such as Liposomes,
Nanoparticles and iron colloids. It may even happen to exist in
route of delivery i.e. locally acting drugs. In most of the cases,
such specialized originator product involves complex IP
barrier, which requires strong business support to move
forward with costly litigation approach.
Other complexity may also exist in drug-device combinations
related to DPI, MDI, nasal spray and transdermal delivery
systems.
Complex generics compete on the basis of their unimaginable
cost, since the bioequivalent version receives market
authorization using the pharmacological and clinical data
produced by the originator. Cost is strictly related to the
availability of raw materials, clinical trial to perform in case of
local acting drugs, to establish sameness characterization of
complex actives.
7. COMPLEX DELIVERY
SYSTEM AS STRATEGY
Complex delivery systems are often being called
as targeted drug delivery systems (TDDS).
TDDS can be parenterally administrable
therapeutic nanoparticles; those typically
comprise an active ingredient together with
organic or inorganic biomaterials, and range from
50 to 200 nm in diameter.
Several classes of therapeutic nanoparticles,
commercially available or in development include
liposomes, albumin-drug complexes and
polymeric nanoparticles.
8. The earliest specialized formulation approved by
U.S. FDA was Doxil® in 1995, for treatment of
Kaposi’s sarcoma.
Doxil® is a longcirculating unilamellar nano-
sized liposome containing doxorubicin.
More recently, there has been interest in targeted
delivery composed of biodegradable polymers,
which offer long circulation characteristic of
liposomes together with controllable drug-release
kinetics mediated by polymer biodegradation.
After parenteral administration, these
formulations can selectively accumulate in
particular tissues or body locations, thereby
enhancing the delivery of the drug payload to the
site of disease.
9. All the targeted delivery systems get access to diseased
tissue through the enhanced permeability and retention
(EPR) effect.
The EPR effect occurs in tumors, sites of inflammation
and other diseased body tissues where the blood vessels
are either disrupted or not fully formed, and as a result
are leakier than normal vessels.
The EPR effect allows nanosystems to pass readily
from the blood vessels into the tumor or inflamed tissue
and to be differentially retained while the drug is
released from the particles.
It has been demonstrated that, as a result of this effect,
therapeutic nanoparticles accumulate in a particular
target tissue location and deliver more of the drug to the
disease site over a longer period of time than a
conventional drug product administered as a solution.
10. • An ideal targeted delivery system must be
precisely optimized to prevent its removal from
the circulation by the body’s defense systems
before it has a chance to reach its target, to
maximize trafficking to the desired location and
to minimize accumulation at sites where the drug
may cause side effects.
• Like conventional pharmaceutical products, it is
necessary to develop a robust and well-controlled
manufacturing process that produces desired
particle/globule size of uniform quality from
batch to batch; however, manufacturing of
complex generics has additional complexities
necessitating precise control over critical
parameters.
11. MANUFACTURING CHALLENGES
Particle size plays key role in all kinds of complex
generic formulations.
Although various techniques are available for
reduction in particle size, adoptability of such
techniques should be established based on vast
experimental knowledge for the particular drug
molecule.
In the case of liposomes or nanoparticles, very small
changes to the manufacturing process can result
profound difference in product characteristics.
Changes to the manufacturing process of
liposomes/nanoparticles can affect the drug content of
the particle and the size and chemical makeup of the
polymer component of the particle.
12. Structural parameters, including the
liposomes/nanoparticles surface properties and sizes,
and the spatial arrangement of the polymer, lipid,
bioactive and targeting ligand, are determined by the
manner in which the particle/vesicle assembles.
Changing any of these factors may alter critical
properties, such as the distribution of the particles in the
body or the rate at which the drug is released from the
particle, thereby resulting in a different clinical
outcome.
Because the analytical tools necessary to characterize
these complex delivery systems and their specific
biological effects are not yet well established, a
generics company may not be able to demonstrate the
degree of sameness of a liposomes/nanoparticles
product required for FDA or other regulatory approval.
13. As such, the manufacturer of the trade or
‘pioneer’ drug could have great exclusivity
advantages by keeping their final manufacturing
process a trade secret or by obtaining process
patents.
If a generics company cannot practice the same
manufacturing process, the generic product
probably does not have the same therapeutic
nanoparticle.
Simply put, because the FDA requires that a
generic product be the “same,” then without the
same process, the generics company will face
considerable difficulties producing the same
product.
14. REGULATORY WITH IP
CHALLENGES
Stringent regulatory requirements exist for the
entry of complex generic. Table 1 lists the
currently approved nanoparticle and liposomal
products in U.S. market.
Despite the fact that many of these products lack
patent protection today and that several generate
worldwide sales of $500–1000 million, most of
these products has no generic equivalent.
In fact, the FDA has never approved parenterally
administered complex generics except in the
recent past for liposomal doxorubicin.
15. No generics company has even attempted to seek
approval for a generic form of a patent-protected
nanoparticle product, and thus there has not been
any patent litigation resulting from a generics
challenge (that is, a “paragraph IV challenge”).
In essence, the technical and manufacturing
complexity, difficulties in demonstrating
bioequivalence and regulatory challenges result in
longer and more expensive development
pathways, which are incompatible with most
generic drug business models.
The two major regulatory difficulties for the
development of Complex generics are
(i) showing bioequivalence and
(ii) FDA requirements for parenteral drug products.
16. For a generic drug company to avoid doing full
clinical trials of safety and effectiveness, they
must show that, among other things, the generic
product is bioequivalent to the pioneer product
that it references and relies on for approval.
For typical, oral, small-molecule products, this
bioequivalence is easily shown by dosing healthy
volunteers and measuring and comparing the
mean area under the plasma concentration curve
and maximum plasma nano concentration of the
drug and then calculating the 90% confidence
interval for the ratio of those mean responses.
17. If that confidence interval is within 80–125% of the pioneer
product for those parameters, the generic product is said to
be bioequivalent. In the case of Complex generics and other
locally acting drugs, the standard approach to the evaluation
of bioequivalence is not sufficient to show sameness with
respect to rate and extent of absorption of the active
pharmaceutical ingredient at the site of action.
To directly demonstrate equivalent drug concentration at
the site of action, a prospective generic company would
have to confront several issues.
First, it would need to test the generic product in individuals
with the target indication because the EPR effect and the
product bio-distribution would be different in healthy
individuals.
Moreover, for most anticancer drugs, testing in healthy
volunteers is not feasible because of the drugs’ toxicity.
Second, non-invasive assays for quantifying active
pharmaceutical ingredients or complex delivery systems in
most tissues do not exist.
18. No assay currently exists to measure the drug
release that occurs at the tissue site as opposed
to other areas in the body.
In principle, the possibilities exist of sampling
the target tissue and analyzing it for the
concentration of encapsulated complex
generics and active in it.
This possibility is only theoretical because the
FDA has never accepted this type of data for a
generic product; at least not before 2 years or
so.
19. COMMUNICATION WITH
REGULATORY AUTHORITY
Meeting with FDA is mandatory because preANDA
of Complex drugs is not covered by GDUFA.
The process needs to be initiated by sending a pre-
ANDA meeting request through OGD
genericsdrugs@FDA.hhs.gov.
Evaluation of the ANDA will start after assigning
the project to a reviewer. Information on product
necessities can also be done through control
correspondence with FDA.
Once meeting request is accepted by FDA may
happen with schedule meeting of grant or denial.
20. If meeting schedule is accepted by FDA, then
applicant/or requester needs to prepare the
meeting package at least 4 weeks before
meeting scheduled and send it to FDA.
Final meeting needs to be thoroughly
questioned with all kinds of challenges with
regard to information needs to be generated in
comparison of RLD.
That is the reason why procuring information
from FDA in order to make the complex
generic equivalent that of innovator/RLD is
also a challenging task ahead after so many
communications with FDA.
21. INTELLECTUAL PROPERTY
The Hatch-Waxman Act (1) also created a delicate balance
between the rights of generic firms and research-based
firms by rewarding exclusivity to the pioneer company for
discovering new drug ingredient and going through the
vigorous FDA regulatory process.
As a result of Hatch-Waxman Act, the FD&C Act requires
that, among other things, one of the following four
certifications be made when filing an ANDA or 505(b) (2)
purposes: Para I: That such patent information has not been
filed.
Para II: That such patent has expired.
Para III: The generic drug will not go on the market until
the patent expiration date passes.
Para IV: The patent in question is invalid, unenforceable, or
will not infringe by the manufacture, use, or sale of the
generic product.